ClinicalTrials.gg
Not yet recruitingNCT07945210Updated Nov 18, 2026

Colistin Heteroresistance in Multidrug-Resistant Gram-Negative Bacilli

An observational study in Bacterial Infections and Gram-Negative Bacterial Infections, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionGram-Negative Bacterial InfectionsRegistry: Bacterial InfectionsReclassifiedWhy we changed it
Registry
Bacterial Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gram-Negative Bacterial Infections
Why
  1. The study's listed conditions name Gram-Negative Bacterial Infections, a narrower term within Bacterial Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assiut University · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
75
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to detect colistin heteroresistance phenotypically and genotypically among multidrug-resistant Gram-negative bacilli isolated from clinical specimens at Assiut University Hospitals.

Read the detailed description

Multidrug-resistant Gram-negative bacterial infections are a major clinical concern. Colistin is used as a last-line therapy, but heteroresistance (presence of resistant subpopulations within a susceptible isolate) may lead to treatment failure and is difficult to detect by routine methods.

This observational study will collect multidrug-resistant Gram-negative isolates that are intermediate to colistin by broth microdilution and will test them for heteroresistance using population analysis profile as the reference method, in addition to gradient strips (Etest) and disc diffusion. Molecular detection of related resistance genes will also be performed.

02

Conditions studied

  • Bacterial Infections
  • Gram-Negative Bacterial Infections

Browse trials for

Keywords

  • Assiut
  • Colistin heteroresistance
  • Multidrug-resistant
  • Gram-negative bacilli
  • Population analysis profile
03

In context

Gram-Negative Bacterial Infections Reclassified

59 studies on the registry are indexed under Gram-Negative Bacterial Infections; 11 are open to participants now.

This study's planned enrollment of 75 is below the median of 249 across 14 observational studies indexed under Gram-Negative Bacterial Infections.

Browse Gram-Negative Bacterial Infections studies →

Lead sponsor

Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Gram-Negative Bacterial Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bacterial Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Multidrug-resistant Gram-negative bacterial isolates obtained from clinical specimens of hospitalized patients at Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Multidrug-resistant Gram-negative isolates from clinical specimens
  • Colistin intermediate confirmed by broth microdilution

Exclusion criteria

Exclusion Criteria:

  • Gram-positive bacteria
  • Carbapenem-sensitive Gram-negative bacteria
  • Repeated samples from the same patient
  • Colistin-resistant isolates confirmed by broth microdilution
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Multidrug-Resistant Gram-Negative Isolates

    Clinical isolates of multidrug-resistant Gram-negative bacilli that are intermediate to colistin and will be tested for heteroresistance.

06

What researchers measure

Primary outcomes

  1. Number of isolates with colistin heteroresistance

    Number of multidrug-resistant Gram-negative isolates showing colistin heteroresistance by population analysis profile test.

    Time frame: Baseline

Secondary outcomes

  1. Number of isolates positive by Etest

    Number of isolates showing colistin heteroresistance by gradient strip (Etest) method.

    Time frame: Baseline

  2. Number of isolates positive by disc diffusion

    Number of isolates showing colistin heteroresistance by disc diffusion method.

    Time frame: Baseline

  3. Number of isolates carrying colistin heteroresistance-related genes

    Number of isolates positive for genes associated with colistin heteroresistance detected by conventional polymerase chain reaction.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 26, 2026
Primary completionEst.
Nov 26, 2027
CompletionEst.
Mar 25, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945210
Lead sponsor
Assiut University
Responsible party
Aliaa Abdelhak Shehab (Resident Physician, Department of Clinical Pathology, Assiut University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 26, 2026 (estimated)
Primary completion
Nov 26, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Aliaa A Abdelrahman, Resident
Contact
Aliaa.14223941@med.aun.edu.eg
01064480804
Mohamed Z Abdel-rahman, prof
study chair · Clinical pathology Department, Assiut University Hospitals
Marwa M Mohammed, prof
study chair · Clinical pathology Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion